February 2020

Cipla Foundation-IISER Pune Centre for Chemistry Education and Research on the IISER Pune campus has been inaugurated by Dr. Yusuf K. Hamied, Non-Executive Chairman, Cipla Ltd. He was accompanied by Mrs. Farida Hamied and Ms. Rumana Hamied, the Managing Trustee of Cipla Foundation. The Centre, housing chemistry research labs along with an in-class demo facility provides space for outreach activities involving teacher and student training and will serve as a platform for developing industry-academia interactions.

U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Treatment with Palforzia may be initiated in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy and may be continued in individuals 4 years of age and older. Those who take Palforzia must continue to avoid peanuts in their diets.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has stopped administration of vaccinations in its HVTN 702 clinical trial of an investigational HIV vaccine. This action was taken because an independent data and safety monitoring board (DSMB) found during an interim review that the regimen did not prevent HIV. Importantly, the DSMB did not express any concern regarding participant safety.

Homicide is a leading cause of death among pregnant and postpartum women in Louisiana, according to an analysis of birth and death records from 2016 and 2017. The study, appearing as a research letter in JAMA Pediatrics, was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health. The research team was led by Maeve E. Wallace, Ph.D., of Tulane University School of Public Health and Tropical Medicine in New Orleans.

The U.S. Food and Drug Administration and the Federal Trade Commission today signed a joint statement regarding enhanced collaboration in support of a robust marketplace for biological products, including the critical adoption of biosimilars and interchangeable products. This joint statement describes key steps the agencies will take to address false or misleading promotion about biosimilars within their respective authorities and deter anti-competitive behavior in this space.